Stoke Therapeutics, Inc

(NASDAQ:STOK)

Latest On Stoke Therapeutics, Inc (STOK):

Date/Time Type Description Signal Details
2023-05-04 17:05 ESTNewsStoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5.15M beats by $1.65MN/A
2023-05-01 14:11 ESTNewsStoke Therapeutics upgraded to neutral at BoA on Dravet candidateN/A
2023-04-26 22:19 ESTNewsStoke Therapeutics a buy at Canaccord on platform for genetic diseasesN/A
2023-04-25 22:00 ESTNewsStoke stock rises after UK regulator nod to start trial of eye disorder drugN/A
2023-03-15 17:15 ESTNewsStoke gets FDA nod to use higher dose of epilepsy drug in ongoing trialN/A
2023-03-06 19:36 ESTNewsStoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41MN/A
2023-02-12 09:04 ESTNewsStoke Therapeutics Looks Unfairly ValuedN/A
2022-11-28 18:27 ESTNewsBuy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeN/A
2022-11-14 15:38 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19MN/A
2022-11-14 15:37 ESTNewsStoke Therapeutics drops 27% after early data for anti-seizure medicineN/A
2022-08-09 08:23 ESTNewsStoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18MN/A
2022-05-10 14:29 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.98, revenue of $3M misses by $34.5MN/A
2022-03-10 22:22 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.04N/A
2022-01-31 23:13 ESTNewsStoke Therapeutics initiated Buy at Jefferies on potential of RNA platformN/A
2022-01-25 02:45 ESTNewsStoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2021-12-03 21:14 ESTNewsStoke Therapeutics shares data from Phase 1/2a trial for STK-001 in Dravet syndromeN/A
2021-12-01 09:31 ESTNewsWarning: STOK is at high risk of performing badlyN/A
2021-12-01 09:31 ESTNewsStoke Therapeutics (STOK) Investor Presentation -SlideshowN/A
2021-11-23 08:45 ESTNewsStoke Therapeutics up 14% following J.P. Morgan upgrade to overweightN/A
2021-11-08 19:21 ESTNewsStoke Therapeutics EPS misses by $0.02N/A
2021-09-22 07:07 ESTNewsStoke Therapeutics posts interim results from early-stage STK-001 Dravet syndrome studyN/A
2021-08-10 12:23 ESTNewsStoke Therapeutics EPS misses by $0.12N/A
2021-03-30 13:19 ESTNewsStoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome studyN/A
2021-03-11 20:54 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 12:29 ESTAnalyst RatingThe Analyst Target Price has increased from $63.75 to $65.38.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-11 00:51 ESTAnalyst RatingThe Analyst Target Price has increased from $60.38 to $63.75.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$2.12 is estimated for the 2022 year.Sell
2021-03-10 04:53 ESTFinancialsCompany financials have been released.Neutral
2021-03-07 14:56 ESTNewsSizing Up Stoke TherapeuticsN/A
2021-02-11 08:36 ESTAnalyst RatingThe Analyst Target Price has increased from $59.5 to $60.38.Neutral
2021-02-10 19:01 ESTNewsStoke cut to neutral at Wedbush seeking a ‘better entry point’N/A
2021-01-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $57.63 to $59.5.Neutral
2021-01-15 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $56.5 to $57.63.Neutral
2020-12-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $54.13 to $56.5.Neutral
2020-12-16 13:07 ESTAnalyst RatingThe Analyst Target Price has increased from $49.13 to $54.13.Neutral
2020-12-14 08:52 ESTAnalyst RatingThe Analyst Target Price has increased from $48.13 to $49.13.Neutral
2020-12-14 08:12 ESTNewsStoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market CapN/A
2020-11-26 21:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 03:45 ESTNewsStoke Therapeutics prices $97.5M public offeringN/A
2020-11-19 00:23 ESTNewsStoke Therapeutics -2.7% AH, proposes public offeringN/A
2020-11-17 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:28 ESTAnalyst RatingThe Analyst Target Price has increased from $47.13 to $48.13.Buy
2020-11-14 21:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:26 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 13:26 ESTAnalyst RatingThe Analyst Target Price has increased from $41.5 to $47.13.Buy
2020-11-13 10:25 ESTNewsStoke Therapeutics EPS in-lineN/A
2020-11-08 00:59 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 18:01 ESTInsider TradeHuw M. Nash has directly disposed of 2,536 shares and currently holds 0 shares.Sell

About Stoke Therapeutics, Inc (STOK):

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

See Advanced Chart

General

  • Name Stoke Therapeutics, Inc
  • Symbol STOK
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2019-06-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.stoketherapeutics.com
View More

Valuation

  • Trailing PE 21.65
  • Price/Book (Most Recent Quarter) 6.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.80
  • Next Year EPS Estimate -$2.10
  • Next Quarter EPS Estimate -$0.44
  • Return on Assets -13%
  • Return on Equity -20%
  • Earnings Per Share -$11.44
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.78 billion
  • EBITDA -22302000
  • PE Ratio -7.4
  • Analyst Target Price $65.38
  • Book Value Per Share $7.14
View More

Share Statistics

  • Shares Outstanding 36.66 million
  • Shares Float 12.64 million
  • % Held by Insiders 170%
  • % Held by Institutions 98.06%
  • Shares Short 3.3 million
  • Shares Short Prior Month 3.37 million
  • Short Ratio 27.54
  • Short % of Float 21%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • 52 Week High $71.58
  • 52 Week Low $17.55
  • 50 Day Moving Average 58.62
  • 200 Day Moving Average 48.97
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Stoke Therapeutics, Inc (STOK) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Stoke Therapeutics, Inc (STOK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.42-$0.420.92%
2020-09-302020-11-12$N/A-$0.41-$0.434.58%
2020-06-302020-08-10$N/A-$0.39-$0.36-8.33%
2020-03-312020-05-15$N/A-$0.34-$0.378.87%
2019-12-312020-03-23$N/A-$0.09-$0.3069.63%
2019-09-302019-11-12$N/A-$0.26-$0.285.83%
2019-06-302019-08-14$N/A-$1.54-$1.635.39%

Stoke Therapeutics, Inc (STOK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 8.9 million N/A N/A 7.22 million 7.09 million
Income Before Tax -14.56 million N/A N/A -11.04 million -10.16 million
Selling General Administrative 5.68 million N/A N/A 4.52 million 3.98 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -14.35 million N/A N/A -11.54 million -11.07 million
Operating Income -14.59 million N/A N/A -11.74 million -11.07 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 15000 N/A N/A 22000 908000
Net Income From Continuing Operations -14.56 million N/A N/A -11.04 million -10.16 million
Net Income Applicable to Common Shares -14.56 million -13.68 million -12.96 million N/A -10.16 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -269000 -81000 -610000 N/A N/A
Change to Liabilities 610000 N/A N/A N/A N/A
Total Cash Flow from Investing Activities -269000 N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 673000 369000 198000 N/A N/A
Change to Operating Activities -80000 N/A N/A N/A N/A
Change in Cash -10.47 million -9.36 million -11.18 million N/A N/A
Total Cash from Operating Activities -10.87 million -9.65 million -10.77 million N/A N/A
Depreciation 234000 224000 193000 N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -360000 N/A N/A N/A N/A
Change to Net Income 2.05 million N/A N/A N/A N/A
Capital Expenditures 269000 81000 610000 N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 11.85 million N/A N/A 6.5 million 4.32 million
Total Stockholder Equity 286.08 million N/A N/A 214.34 million 224.43 million
Other Current Liabilities N/A N/A N/A 54000 N/A
Total Assets 297.93 million N/A N/A 220.84 million 228.75 million
Common Stock 4000 3000 3000 N/A 3000
Other Current Assets 6.62 million 378000 N/A N/A N/A
Retained Earnings -110.28 million -95.72 million -82.03 million -69.07 million -58.04 million
Other Liabilities N/A 665000 1.01 million N/A 221000
Other Assets N/A 205000 205000 N/A 205000
Cash 287.31 million N/A N/A 211.29 million 222.47 million
Total Current Liabilities 11.43 million 6.74 million N/A 5.46 million 4.1 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 2.68 million 4.27 million 4.47 million N/A 2.51 million
Total Current Assets 293.93 million 195.46 million N/A 215.77 million 226.03 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 286.08 million 192.54 million 203.4 million N/A 224.43 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 11.43 million 1.1 million N/A 1.78 million 751000

Stoke Therapeutics, Inc (STOK) Chart:

Stoke Therapeutics, Inc (STOK) News:

Below you will find a list of latest news for Stoke Therapeutics, Inc (STOK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Stoke Therapeutics, Inc (STOK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-202.50CALL0 01045.43TRUE00
2025-06-2050CALL0 0613.36TRUE00
2025-06-207.50CALL0 0377.81TRUE00
2025-06-20100.55CALL0 18449.81TRUE00
2025-06-2012.50.1CALL20 2757.2FALSE0.10
2025-06-20150CALL0 0388.98FALSE00
2025-06-202.50PUT0 00FALSE00
2025-06-2050PUT0 2182.02FALSE00
2025-06-207.50PUT0 13528.71FALSE00
2025-06-20100.63PUT0 3866.93FALSE00
2025-06-2012.53.1PUT0 2064.77TRUE00
2025-06-20150PUT0 0183.51TRUE00
2025-07-182.50CALL0 0745.65TRUE00
2025-07-1850CALL0 0390.28TRUE00
2025-07-187.50CALL0 30141.05TRUE00
2025-07-18101.4CALL11 3157.58TRUE0.50.56
2025-07-1812.50CALL0 0133.3FALSE00
2025-07-18150CALL0 163.19FALSE00
2025-07-1817.50CALL0 0269.05FALSE00
2025-07-18200CALL0 0293.55FALSE00
2025-07-182.50PUT0 0629.65FALSE00
2025-07-1850PUT0 0522.55FALSE00
2025-07-187.50.25PUT0 7107.01FALSE00
2025-07-18100PUT0 0199.13FALSE00
2025-07-1812.50PUT0 083.91TRUE00
2025-07-18150PUT0 0120.98TRUE00
2025-07-1817.50PUT0 0141.29TRUE00
2025-07-18200PUT0 0154.6TRUE00
2025-08-152.50CALL0 0584.88TRUE00
2025-08-1550CALL0 0305.57TRUE00
2025-08-157.50CALL0 588.29TRUE00
2025-08-15101.9CALL10 5373.09TRUE1.90
2025-08-1512.50CALL0 3154.34FALSE00
2025-08-15150.2CALL0 12186.62FALSE00
2025-08-1517.50CALL0 0210.75FALSE00
2025-08-15200CALL0 1230.01FALSE00
2025-08-1522.50CALL0 0246.02FALSE00
2025-08-15250CALL0 1259.68FALSE00
2025-08-152.50PUT0 01199.21FALSE00
2025-08-1550PUT0 12411.49FALSE00
2025-08-157.50PUT0 56787.11FALSE00
2025-08-15101.25PUT3 491.86FALSE1.250
2025-08-1512.50PUT0 032.65TRUE00
2025-08-15150PUT0 096.73TRUE00
2025-08-1517.50PUT0 0109.86TRUE00
2025-08-15200PUT0 0127.74TRUE00
2025-08-1522.50PUT0 0139.01TRUE00
2025-08-15250PUT0 0151.88TRUE00
2025-09-192.50CALL0 0456.55TRUE00
2025-09-1950CALL0 9250.32TRUE00
2025-09-197.50CALL0 029.56TRUE00
2025-09-19100CALL0 395.26TRUE00
2025-09-1912.53CALL0 396.46FALSE00
2025-09-19150.35CALL1 2758FALSE-0.7-0.67
2025-09-1917.50.5CALL0 3179.21FALSE00
2025-09-19200.05CALL0 0188.62FALSE00
2025-09-192.50PUT0 0413.79FALSE00
2025-09-1950.05PUT0 1339.59FALSE00
2025-09-197.50PUT0 13149.79FALSE00
2025-09-19100PUT0 0141.09FALSE00
2025-09-1912.50PUT0 074.81TRUE00
2025-09-19150PUT0 065.88TRUE00
2025-09-1917.50PUT0 095.23TRUE00
2025-09-19200PUT0 0104.74TRUE00
2025-11-212.50CALL0 0380.84TRUE00
2025-11-2150CALL0 10205.17TRUE00
2025-11-217.50CALL0 359.83TRUE00
2025-11-21102.25CALL1 374.39TRUE2.250
2025-11-2112.50CALL0 075.69FALSE00
2025-11-21150CALL0 098.8FALSE00
2025-11-2117.50CALL0 0101.59FALSE00
2025-11-212.50PUT0 10829.83FALSE00
2025-11-2150PUT0 0223.66FALSE00
2025-11-217.51.15PUT0 11106.42FALSE00
2025-11-21100PUT0 576.7FALSE00
2025-11-2112.50PUT0 088.98TRUE00
2025-11-21150PUT0 090.15TRUE00
2025-11-2117.50PUT0 088.5TRUE00

Latest STOK Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST13$10.47
Jun 13, 2022 7:59 PM EST60$10.47
Jun 13, 2022 7:59 PM EST20$10.47
Jun 13, 2022 7:59 PM EST41$10.47
Jun 13, 2022 7:59 PM EST15$10.47

Stoke Therapeutics, Inc (STOK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2019-04-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019007260/0000000000-19-007260-index.htm
2019-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019008485/0000000000-19-008485-index.htm
2019-06-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009270/0000000000-19-009270-index.htm
2019-06-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009719/0000000000-19-009719-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000020006449/0000000000-20-006449-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963819000658/0000929638-19-000658-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963820000333/0000929638-20-000333-index.htm
2019-03-26DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319002845/0000950123-19-002845-index.htm
2019-04-30DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003688/0000950123-19-003688-index.htm
2019-04-30DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003690/0000950123-19-003690-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000110465920021017/0001104659-20-021017-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419031374/0001144204-19-031374-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419032095/0001144204-19-032095-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/0001193125-19-155301-index.htm
2019-05-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519155321/0001193125-19-155321-index.htm
2019-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519163789/0001193125-19-163789-index.htm
2019-06-07S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/0001193125-19-167576-index.htm
2019-06-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519167579/0001193125-19-167579-index.htm
2019-06-118-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519170268/0001193125-19-170268-index.htm
2019-06-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519171310/0001193125-19-171310-index.htm
2019-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519171314/0001193125-19-171314-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173255/0001193125-19-173255-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173266/0001193125-19-173266-index.htm
2019-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312519175848/0001193125-19-175848-index.htm
2019-06-18S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519175863/0001193125-19-175863-index.htm
2019-06-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519176488/0001193125-19-176488-index.htm
2019-07-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1623526/000119312519186323/0001193125-19-186323-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519220567/0001193125-19-220567-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519308649/0001193125-19-308649-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520005877/0001193125-20-005877-index.htm
2020-03-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520082470/0001193125-20-082470-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520108110/0001193125-20-108110-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113542/0001193125-20-113542-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113561/0001193125-20-113561-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520139879/0001193125-20-139879-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520160684/0001193125-20-160684-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520189990/0001193125-20-189990-index.htm
2020-07-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312520191098/0001193125-20-191098-index.htm
2020-07-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312520193961/0001193125-20-193961-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520221818/0001193125-20-221818-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520226962/0001193125-20-226962-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520265127/0001193125-20-265127-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021312/0001209191-20-021312-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021314/0001209191-20-021314-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021317/0001209191-20-021317-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021319/0001209191-20-021319-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021321/0001209191-20-021321-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021322/0001209191-20-021322-index.htm
2020-04-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024540/0001209191-20-024540-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032142/0001209191-20-032142-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032146/0001209191-20-032146-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034721/0001209191-20-034721-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034723/0001209191-20-034723-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/0001209191-20-034729-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034731/0001209191-20-034731-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034732/0001209191-20-034732-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034735/0001209191-20-034735-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034737/0001209191-20-034737-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-06-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1623526/000135445719000309/0001354457-19-000309-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009407/0001493152-19-009407-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009851/0001493152-19-009851-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315220002386/0001493152-20-002386-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/0001564590-19-032126-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459019042621/0001564590-19-042621-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019042891/0001564590-19-042891-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020012112/0001564590-20-012112-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1623526/000156459020012202/0001564590-20-012202-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020025636/0001564590-20-025636-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020025637/0001564590-20-025637-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020038587/0001564590-20-038587-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020038905/0001564590-20-038905-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013623/0001567619-19-013623-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013624/0001567619-19-013624-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013625/0001567619-19-013625-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013626/0001567619-19-013626-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013627/0001567619-19-013627-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013628/0001567619-19-013628-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013629/0001567619-19-013629-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013630/0001567619-19-013630-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013631/0001567619-19-013631-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013632/0001567619-19-013632-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013633/0001567619-19-013633-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013662/0001567619-19-013662-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018220/0001567619-19-018220-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018221/0001567619-19-018221-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018222/0001567619-19-018222-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018223/0001567619-19-018223-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018224/0001567619-19-018224-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/0001567619-19-018225-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021770/0001567619-19-021770-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021771/0001567619-19-021771-index.htm
2014-11-24DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352614000001/0001623526-14-000001-index.htm
2018-11-02DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352618000002/0001623526-18-000002-index.htm
2019-06-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999519001367/9999999995-19-001367-index.htm
2020-07-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999520001866/9999999995-20-001866-index.htm
2019-06-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005333/9999999997-19-005333-index.htm
2019-06-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005455/9999999997-19-005455-index.htm

Stoke Therapeutics, Inc (STOK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stoke Therapeutics, Inc (STOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 170%
Institutional Ownership: 9806%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-02Huw M. NashCOO & CBOSell15,995.0026.37421,852.130.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell500.0027.4813,742.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-07-01Huw M. NashCOO & CBOSell3,800.0023.1587,967.720.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-07Huw M. NashCOO & CBOSell913.0022.4120,456.860.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-16Huw M. NashCOO & CBOSell1,900.0025.0647,614.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-03Huw M. NashCOO & CBOSell5,700.0024.73140,943.330.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-28Huw M. NashCOO & CBOSell2,081.0030.0062,430.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-01Huw M. NashCOO & CBOSell700.0028.7120,097.630.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-08Huw M. NashCOO & CBOSell30,718.0030.00921,540.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-09-09Huw M. NashCOO & CBOSell17,201.0030.00516,030.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-01Huw M. NashCOO & CBOSell2,300.0034.8680,182.600.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOSell2,536.0037.9896,324.890.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-07-07Robin A. WalkerChief Legal Officer, CCO & SecSell941.0022.5021,172.500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-11-02Stephen J TulipanoCFOSell14,445.0037.86546,909.371,002.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy131,147.000.6078,688.20131,147.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-03-31Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevSell7,500.0030.00225,000.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell1,230.0027.4833,801.5113,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevSell1,649.0040.0065,960.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevSell5,851.0040.00234,041.7613,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell7,225.0038.42277,585.9513,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell7,875.0026.91211,920.9814,730.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevBuy1,649.000.60989.4015,149.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-11-02Stephen J TulipanoCFOSell20,155.0036.79741,448.0315,447.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOSell33,148.0025.66850,697.0115,995.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2019-06-21Apple Tree Partners IV, L.P.10% Share HolderBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-21Seth Loring HarrisonDirectorBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2020-11-04Stephen J TulipanoCFOSell16,941.0040.03678,085.5516,929.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-09-09Huw M. NashCOO & CBOBuy17,201.002.1937,670.1917,201.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Barry TichoChief Medical OfficerSell365.0027.9810,212.70172,662.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerSell1,000.0027.1727,174.00173,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy42,880.002.1993,907.20174,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-07-16Huw M. NashCOO & CBOBuy1,900.002.194,161.001,900.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevBuy5,851.000.603,510.6019,351.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell24,775.0037.64932,578.0720,725.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-08-28Huw M. NashCOO & CBOBuy2,081.002.194,557.392,081.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0021,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Huw M. NashCOO & CBOBuy2,107.002.194,614.332,107.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell10,895.0025.82281,314.3522,605.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-01Huw M. NashCOO & CBOSell3,400.0034.33116,717.922,300.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-03Stephen J TulipanoCFOBuy1,732.004.487,759.362,334.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-02Huw M. NashCOO & CBOSell3,164.0036.59115,785.002,536.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-09-08Huw M. NashCOO & CBOBuy30,718.002.1967,272.4230,718.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevBuy20,000.002.1943,800.0033,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2019-06-19RTW INVESTMENTS, LP10% Share HolderBuy555,556.0018.0010,000,008.003,355,466.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2020-11-04Stephen J TulipanoCFOBuy33,268.004.48149,040.6433,870.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-10-01RTW INVESTMENTS, LP10% Share HolderBuy31,560.0021.96693,029.203,387,026.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-10-30RTW INVESTMENTS, LP10% Share HolderBuy41,438.0028.791,193,004.163,428,464.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-10-31RTW INVESTMENTS, LP10% Share HolderBuy18,747.0028.15527,658.693,447,211.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-01RTW INVESTMENTS, LP10% Share HolderBuy8,598.0028.61245,950.093,455,809.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-08RTW INVESTMENTS, LP10% Share HolderSell16,434.0028.70471,631.153,544,248.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-11-02Stephen J TulipanoCFOBuy35,000.004.48156,800.0035,602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-11-04RTW INVESTMENTS, LP10% Share HolderBuy104,873.0029.243,066,843.093,560,682.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2020-07-01Huw M. NashCOO & CBOBuy3,800.002.198,322.003,800.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy30,497.000.6018,298.2043,997.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy1,503.002.193,291.5745,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-03-02Huw M. NashCOO & CBOBuy42,779.002.1993,686.0149,103.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell1,607.0027.0843,521.26500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2019-12-16Edward M. MD KayeCEOBuy50,000.000.6030,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-08-03Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-09-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-10-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-04Stephen J TulipanoCFOSell11,111.0041.42460,214.295,818.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-12-20Gene LiauEVP Research & Preclinical DevBuy6,000.000.603,600.006,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-11-02Stephen J TulipanoCFOSell400.0038.4415,374.00602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-03Stephen J TulipanoCFOSell1,732.0039.8468,997.51602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-04Stephen J TulipanoCFOSell5,216.0041.97218,909.78602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOBuy6,324.000.402,529.606,324.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-09-01Huw M. NashCOO & CBOSell5,000.0027.60138,015.00700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm